Superficial Basal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Superficial Basal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma [NA]
A clinical trial update notes an active-not-recruiting study evaluating optical coherence tomography-guided laser treatment for basal cell c…
-
FDA approval · 2021-01-26FDA Approved: IMIQUIMOD — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical's Imiquimod as an Original Application (generic) product. It covers actinic keratosis, superficial basal…
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma [Phase 1, Phase 2]
This update reports the completion of a dose-ranging Phase 1/2 trial evaluating topical creams containing API 31510 for superficial basal ce…
-
CLINICAL_TRIALS research · 2014-01-31Clinical Trial Update: Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate [Phase 4]
A Phase 4 clinical trial compares topical photodynamic therapy using 5-aminolevulinic acid (20%) with two-stage methylaminolevulinate for su…
-
FDA approval · 2012-03-06FDA Approved: IMIQUIMOD — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's generic imiquimod 5% cream (ANDA 201994) as an original application, expanding access to the dermatology indications…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2012-02-14FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for ZYCLARA (imiquimod) to update the labeling with new or expanded indications.
-
CLINICAL_TRIALS trial_result · 2008-11-26Clinical Trial Update: Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream [Phase 3]
Phase 3 open-label trial evaluating whether imiquimod 5% cream clears superficial basal cell carcinoma.